Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Status:
Completed
Trial end date:
2020-11-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and feasibility of administering
investigational drugs (meaning not Food and Drug Administration (FDA)-approved for kidney
cancer) prior to surgical treatment for kidney cancer. The first drug is called MEDI4736, and
the second drug is called tremelimumab. Both of these drugs work by attaching to certain
proteins on immune cells with the goal of stimulating an immune response against cancer
cells. This is a phase 1 trial, with the primary goal of identifying if this treatment is
safe and possible side effects when given prior to surgery for kidney cancer.